Predicted coverage by 4CMenB vaccine against invasive meningococcal disease cases in the Netherlands

被引:14
作者
Freudenburg-de Graaf, W. [1 ,2 ]
Knol, M. J. [3 ]
van der Ende, A. [1 ,2 ]
机构
[1] Univ Amsterdam, Dept Med Microbiol & Infect Prevent, Amsterdam UMC, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands
[2] Netherlands Reference Lab Bacterial Meningitis, Amsterdam, Netherlands
[3] Natl Inst Publ Hlth & Environm, Ctr Infect Dis Control Netherlands, Bilthoven, Netherlands
基金
英国惠康基金;
关键词
Neisseria meningitidis; 4CMenB vaccine; Whole-genome sequencing; gMATS; B VACCINE; BACTERICIDAL ANTIBODIES; PERSISTENCE; AGE; IMMUNOGENICITY; IMMUNIZATION; ADOLESCENTS; INFANTS; STRAIN;
D O I
10.1016/j.vaccine.2020.10.008
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Neisseria meningitidis serogroup B is a major cause of invasive meningococcal disease in Europe. In the absence of a conjugate serogroup B vaccine, a subcapsular 4CMenB vaccine was developed. Data on 4CMenB vaccine efficacy is still limited. Recently, genomic MATS (Meningococcal Antigen Typing System) was developed as a tool to predict strain coverage, using vaccine antigens sequence data. We characterized all invasive meningococcal isolates received by the Netherlands Reference Laboratory for Bacterial Meningitis (NRLBM) in two epidemiological years 2017-2019 using whole-genome sequencing and determined serogroup, clonal complex (cc) and estimated 4CMenB vaccine coverage by gMATS. Of 396 cases of invasive meningococcal disease, corresponding to an incidence of 1.22 cases/10(5) inhabitants, 180 (45%) were serogroup W, 155 (39%) serogroup B, 46 (12%) serogroup Y, 10 (3%) serogroup C, 2 non-groupable (0.5%) and 3 (0.7%) unknown. The incidence was the highest among 0-4 years olds (4 cases/10(5) inhabitants), and 57/72 (79%) of these cases were serogroup B. Serogroup W predominated among persons 45 years of age or older with 110/187 (59%) cases. Serogroup B isolates comprised 11 different clonal complexes, with 103/122 (84%) isolates belonging to 4 clonal complexes: cc32, cc41/44, cc269 and cc213. In contrast, serogroup W isolates were genetically similar with 95% belonging to ccl 1. Of 122 serogroup B isolates, 89 (73%; 95% CI: 64-80%) were estimated to be covered by 4CMenB and the degree of coverage varied largely by clonal complex and age. Among the 0-4 year olds, 25 of 43 (58%; 95% CI: 43-72%) MenB isolates were estimated to be covered. Since the coverage of the 4CMenB vaccine is dependent on circulating clonal complexes, our findings emphasize the need for surveillance of circulating meningococcal strains. In addition, estimation of age specific coverage is relevant to determine the right target age group for vaccination. (C) 2020 The Authors. Published by Elsevier Ltd.
引用
收藏
页码:7850 / 7857
页数:8
相关论文
共 50 条
  • [1] Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Portugal
    Simoes, Maria Joao
    Bettencourt, Celia
    De Paola, Rosita
    Giuliani, Maria
    Pizza, Mariagrazia
    Moschioni, Monica
    Machado, Jorge
    PLOS ONE, 2017, 12 (05):
  • [2] Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment
    Vogel, Ulrich
    Taha, Muhamed-Kheir
    Vazquez, Julio A.
    Findlow, Jamie
    Claus, Heike
    Stefanelli, Paola
    Caugant, Dominique A.
    Kriz, Paula
    Abad, Raquel
    Bambini, Stefania
    Carannante, Anna
    Deghmane, Ala Eddine
    Fazio, Cecilia
    Frosch, Matthias
    Frosi, Giacomo
    Gilchrist, Stefanie
    Giuliani, Marzia M.
    Hong, Eva
    Ledroit, Morgan
    Lovaglio, Pietro G.
    Lucidarme, Jay
    Musilek, Martin
    Muzzi, Alessandro
    Oksnes, Jan
    Rigat, Fabio
    Orlandi, Luca
    Stella, Maria
    Thompson, Danielle
    Pizza, Mariagrazia
    Rappuoli, Rino
    Serruto, Davide
    Comanducci, Maurizio
    Boccadifuoco, Giuseppe
    Donnelly, John J.
    Medini, Duccio
    Borrow, Ray
    LANCET INFECTIOUS DISEASES, 2013, 13 (05) : 416 - 425
  • [3] Evolution of strain coverage by the multicomponent meningococcal serogroup B vaccine (4CMenB) in France
    Hong, Eva
    Terrade, Aude
    Muzzi, Alessandro
    De Paola, Rosita
    Boccadifuoco, Giuseppe
    La Gaetana, Rita
    Deghmane, Ala-Eddine
    Pizza, Mariagrazia
    Serino, Laura
    Taha, Muhamed-Kheir
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2021, 17 (12) : 5614 - 5622
  • [4] Genomic Characterization of Invasive Meningococcal Serogroup B Isolates and Estimation of 4CMenB Vaccine Coverage in Finland
    Bodini, Margherita
    Brozzi, Alessandro
    Giuliani, Maria
    Nohynek, Hanna
    Vainio, Anni
    Kuusi, Markku
    De Paola, Rosita
    Pizza, Mariagrazia
    Medini, Duccio
    Toropainen, Maija
    Serino, Laura
    Muzzi, Alessandro
    MSPHERE, 2020, 5 (05):
  • [5] Genetic characterization and estimated 4CMenB vaccine strain coverage of 284 Neisseria meningitidis isolates causing invasive meningococcal disease in Argentina in 2010-2014
    Efron, Adriana
    Brozzi, Alessandro
    Biolchi, Alessia
    Bodini, Margherita
    Giuliani, Maria
    Guidotti, Silvia
    Lorenzo, Federico
    Moscoloni, Maria Alicia
    Muzzi, Alessandro
    Nocita, Florencia
    Pizza, Mariagrazia
    Rappuoli, Rino
    Tomei, Sara
    Vidal, Gabriela
    Vizzotti, Carla
    Campos, Josefina
    Sorhouet Pereira, Cecilia
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2024, 20 (01)
  • [6] Effectiveness of a Meningococcal Group B Vaccine (4CMenB) in Children
    Castilla, J.
    Garcia Cenoz, M.
    Abad, R.
    Sanchez-Cambronero, L.
    Lorusso, N.
    Izquierdo, C.
    Canellas Llabres, S.
    Roig, J.
    Malvar, A.
    Gonzalez Carril, F.
    Boone, A. L. D.
    Perez Martin, J.
    Rodriguez Recio, M. J.
    Galmes, A.
    Caballero, A.
    Garcia Rojas, A.
    Juanas, F.
    Nieto, M.
    Viloria Raymundo, L. J.
    Martinez Ochoa, E.
    Rivas, A., I
    Castrillejo, D.
    Moreno Perez, D.
    Martinez, A.
    Borras, E.
    Sanchez Gomez, A.
    Pastor, E.
    Nartallo, V
    Arteagoitia, J. M.
    Alvarez-Fernandez, B.
    Garcia Pina, R.
    Fernandez Arribas, S.
    Vanrell, J.
    Garcia Hernandez, S.
    Mendoza, R. M.
    Mendez, M.
    Lopez-Tercero, M. M.
    Fernandez-Rodriguez, A.
    Blanco, A.
    Carrillo de Albornoz, F. J.
    Ruiz Olivares, J.
    Ruiz-Montero, R.
    Limia, A.
    Navarro-Alonso, J. A.
    Vazquez, J. A.
    Barricarte, A.
    NEW ENGLAND JOURNAL OF MEDICINE, 2023, 388 (05) : 427 - 438
  • [7] Predicted Strain Coverage of a New Meningococcal Multicomponent Vaccine (4CMenB) in Spain: Analysis of the Differences with Other European Countries
    Abad, Raquel
    Medina, Veronica
    Stella, Maria
    Boccadifuoco, Giuseppe
    Comanducci, Maurizio
    Bambini, Stefania
    Muzzi, Alessandro
    Vazquez, Julio A.
    PLOS ONE, 2016, 11 (03):
  • [8] MATS: Global coverage estimates for 4CMenB, a novel multicomponent meningococcal B vaccine
    Medini, Duccio
    Stella, Maria
    Wassil, James
    VACCINE, 2015, 33 (23) : 2629 - 2636
  • [9] Diversity of greek meningococcal serogroup B isolates and estimated coverage of the 4CMenB meningococcal vaccine
    Tzanakaki, Georgina
    Hong, Eva
    Kesanopoulos, Konstatinos
    Xirogianni, Athanasia
    Bambini, Stefania
    Orlandi, Luca
    Comanducci, Maurizio
    Muzzi, Alessandro
    Taha, Muhamed-Kheir
    BMC MICROBIOLOGY, 2014, 14
  • [10] Timing of meningococcal vaccination with 4CMenB (Bexsero®) in children with invasive meningococcal group B (MenB) disease in England
    Ladhani, Shamez N.
    Campbell, Helen
    Amin-Chowdhury, Zahin
    Lucidarme, Jay
    Borrow, Ray
    Ramsay, Mary E.
    VACCINE, 2022, 40 (10) : 1493 - 1498